Literature DB >> 1690235

Chemically induced CD4 mutants of a human T cell line. Evidence for dissociation between binding of HIV I envelope and susceptibility to HIV I infection and syncytia formation.

K Hillman1, O Shapira-Nahor, M F Gruber, J Hooley, J Manischewitz, R Seeman, L Vujcic, S J Geyer, H Golding.   

Abstract

This study describes the derivation of a series of mutants from the human leukemic cell line CEM using the frame shift mutagen Ethyl-methanesulfonate followed by negative selection with multiple treatments of OKT4A + C, and sorting into CD4-, CD4-dull, and CD4-intermediate mutants. These mutants express reduced CD4 levels ranging from 0 to 60% of the parental line. The mutants were analyzed by staining with a battery of CD4-specific mAb, by assessing their ability to bind soluble gp120, and by their ability to form syncytia after infection with cell-free HIV I virus and a gp160-vaccinia vector. Two groups of particularly interesting mutants were identified: (1) CD4-dull mutants expressing only 5 to 10% of the wild type surface CD4 density, which nevertheless were infectable by HIV I and produced as many syncytia and reverse transcriptase activity as the parental line after infection with gp160-vaccinia or cell free HIV I. (2) CD4-intermediate mutants (30 to 60% of parental CD4 level), which express CD4-epitopes required for interaction with the HIV I envelope protein, yet are markedly deficient in their ability to form syncytia after gp160-vaccinia or HIV I infection. Two of these mutants did form syncytia after transient reconstitution with a wild type CD4 containing vaccinia vector. Inasmuch as they were found to bind soluble gp120 with the same avidity as other, functionally normal, CD4-intermediate mutants, these human T cell mutants may have a reduced susceptibility to HIV I infection due to the absence of a "fusogenic component" or to a structural alteration in a region of the CD4 molecule not required for binding of the HIV I envelope, but for the subsequent fusion and entry process.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690235

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  D S Dimitrov; K Hillman; J Manischewitz; R Blumenthal; H Golding
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  S Lee; C K Lapham; H Chen; L King; J Manischewitz; T Romantseva; H Mostowski; T S Stantchev; C C Broder; H Golding
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Phorbol ester-induced down modulation of tailless CD4 receptors requires prior binding of gp120 and suggests a role for accessory molecules.

Authors:  H Golding; D S Dimitrov; J Manischewitz; C C Broder; J Robinson; S Fabian; D R Littman; C K Lapham
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

4.  Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  D S Dimitrov; R Blumenthal
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction.

Authors:  D S Dimitrov; C C Broder; E A Berger; R Blumenthal
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

6.  Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.

Authors:  L Burkly; N Mulrey; R Blumenthal; D S Dimitrov
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4.

Authors:  J A Hoxie; L F Brass; C H Pletcher; B S Haggarty; B H Hahn
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

8.  Cell fusion mediated by interaction of a hybrid CD4.CD8 molecule with the human immunodeficiency virus type 1 envelope glycoprotein does occur after a long lag time.

Authors:  H Golding; R Blumenthal; J Manischewitz; D R Littman; D S Dimitrov
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion.

Authors:  C C Broder; E A Berger
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells.

Authors:  H Golding; J Manischewitz; L Vujcic; R Blumenthal; D S Dimitrov
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.